|
|
|
|
||
SupportWe are nearing the 200 sma at 102.90. Hope to see that level act as support. Frustrating to watch hznp drop while IBB rises. In an effort to keep it real, VRDN dosed their first subject in their trial of their next generation uricase with half life extension technology for subcutaneous dosing for TED patients. I took a small position as a hedge. https://investors.viridiantherapeutics.com/news-releases/news-release-details/viridian-therapeutics-doses-first-subject-first-human-clinical |
return to message board, top of board |